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Atomic structures of Coxsackievirus A6 and its
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Coxsackievirus A6 (CVA6) has recently emerged as a major cause of hand, foot and mouth
disease in children worldwide but no vaccine is available against CVA6 infections. Here, we
demonstrate the isolation of two forms of stable CVA6 particles-procapsid and A-particle-
with excellent biochemical stability and natural antigenicity to serve as vaccine candidates.
Despite the presence (in A-particle) or absence (in procapsid) of capsid-RNA interactions,
the two CVA6 particles have essentially identical atomic capsid structures resembling the
uncoating intermediates of other enteroviruses. Our near-atomic resolution structure of
CVA6 A-particle complexed with a neutralizing antibody maps an immune-dominant neu-
tralizing epitope to the surface loops of VP1. The structure-guided cell-based inhibition
studies further demonstrate that these loops could serve as excellent targets for designing
anti-CVA6 vaccines.
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Coxsackievirus A6 (CVA6), a member of the humanEnterovirus species A (family Picornaviridae, genusEnterovirus), has recently emerged as one of the major
pathogens of hand, foot, and mouth disease (HFMD) in children
worldwide1. CVA6 was associated with many HFMD outbreaks
in Asia2, Europe3, and North America4, 5. Unlike the ‘classical’
enteroviruses, including enterovirus 71 (EV71) and Coxsackivirus
A16 (CVA16), CVA6 infection can lead to many atypical clinical
symptoms such as vesiculobullous eruption6, onychomadesis7 or
herpangina8. In addition, CVA6 can cause serious central nervous
system disorders such as aseptic meningitis and brainstem
encephalitis9, 10. Indeed, CVA6 is considered to be as pathogenic
as, if not more than, EV71 and CVA16. Although highly effective
vaccines exist for EV7111, no vaccine is available for the global
public health threats imposed by CVA6, which underscores the
critical need for developing an effective vaccine.
Atomic structures of EV71 and CVA16 have helped propel
progress in vaccine design targeted against these picornavirus
infections12, 13. The structures of different types of EV71, CVA16
and other picornavirus particles and their immune-complexes
have been extensively studied at or near atomic resolution by
means of cryo-electron microscopy (cryoEM) or X-ray crystal-
lography12, 14–19. Such structural knowledge has also provided
key insights into the picornaviral life cycle, including mechanisms
of receptor binding and accompanying conformational changes,
cell entry and genome release, and viral assembly. Two types of
stable particles are typically isolated: mature virions (containing
RNA genome) and procapsid (empty, lacking RNA genome)12, 20.
The mature particle of typical picornaviruses contains sixty copies
each of four unique structural proteins (VP1, VP2, VP3, and
VP4) arranged with pseudo T= 3 symmetry21, 22. VP1, VP2, and
VP3 all have a compact core structure consisting of a classical, β-
sandwich, jelly-roll fold, which forms the bulk of the capsid and
each of these protein subunits also have several loops that dec-
orate the outer surface of the capsid. Unlike the other viral pro-
teins, VP4 adopts an extended conformation on the inner surface
of the mature capsid21, 22. Upon binding of cellular receptor(s) at
the surface depression (canyon) encircling each icosahedral 5-fold
vertex12, 23, mature virus releases the lipid moiety (pocket factor)
buried in a hydrophobic pocket formed by VP1 beneath the
canyon. Loss of pocket factor allows the pocket to collapse and a
channel close to the icosahedral 2-fold axis to open, leading to an
expanded, third type of particle, called uncoating intermediate or
A-particle14, 15, 24–26. Although A-particles are characterized by
their inherent instability, the structures of some of them have
been successfully studied by examining particles to which
receptors were bound26, or by treating them with heat or low
pH15, 27, 28. The structures of these A-particles show several
distinctive features including expanded capsids, open channels at
the 2-fold axes, and capsid-RNA interactions15, 26–28.
Though empty and full CVA6 particles have been isolated,
there has not been systematic characterization for any of these
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Fig. 1 Stability infectivity and immunogenicity of CVA6 particles. a PaSTRy assays of CVA6 procapsids, A-particles and CVA16 mature virions. The high
fluorescence level throughout the whole temperature range indicates the genome in CVA6 A-particle is more exposed than the one in CVA16 mature
virion. In addition, the genomes in CVA6 and CVA16 virions both reach their maximum exposures at ~52 °C, presumably due to capsid expansion triggered
by heat treatment. b, c The thermal stability of CVA6 procapsid b and A-particle c measured at pH values ranging from 5.5 to 8.5. The first derivatives
(-R’ (T)) vs temperature are plotted at different pHs. Both particles are most stable at pH 5.5. d The infectivity of the CVA6 A-particle (3.6 × 107 TCID50/
mg) estimated by TCID50 assays on RD cells (mean± s.d.). e In vitro neutralizing titer of antisera of CVA6 particles. Four groups of mice, each including six
female BALB/c mice, were vaccinated subcutaneously with CVA6 procapsid, A-particle, heating-inactivated (HI) A-particle and adjuvant (control) at days
0 and 21. Blood samples of the mice were assayed at day 35 and the level of neutralization antibody titer of all mice in each group were plotted
(mean± s.d.). f In vivo protective efficacy of antisera of CVA6 particles. The infected mice were treated with antisera against procapsid, A-particle and HI-
A-particle respectively and all three experimental groups had a 100% survival rate compared to 0% for the adjuvant control group
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particles to date and whether they are similar to or different from
the above three types of picornavirus particles remains unclear29.
Although CVA6 shares high (~67%) amino-acid identity with
EV71 and CVA1630, CVA6 recognizes a different cellular
receptor31, 32, suggesting CVA6 may differ in its mode of infec-
tion, or perhaps even in its local structures involved in infection.
Here, we demonstrate the isolation of two stable CVA6 particles
with excellent natural antigenicity: one empty (CVA6 procapsid)
and the other infectious (CVA6 A-particle). The capsid structures
of CVA6 procapsid and A-particle at near atomic (~3 Å) reso-
lution both closely resemble those of the uncoating intermediates
of other enteroviruses. In addition, structural and functional
studies of the CVA6 A-particle complexed with the Fab of a
neutralizing antibody identify four surface loops on VP1 that can
be targeted for vaccine design.
Results
CVA6 procapsids and A-particles as viable vaccine candidates.
CVA6 was grown in human rhabdomyosarcoma (RD) cells and
purified following routine protocols employing centrifugation,
ultracentrifugation, and ultrafiltration. Two types of particles
were purified for subsequent biochemical and structural analyses
(Supplementary Fig. 1a). The top band exhibited a λ260/λ280
absorbance ratio of 0.71, and the particles in that band sedi-
mented with a coefficient of 84S (Supplementary Fig. 1b), had a
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Fig. 2 CryoEM structures of CVA6 procapsid and A-particle. a, b Iso-contoured views (radially colored) of cryoEM density maps of procapsid a and
A-particle b viewed along a 2-fold axis. One icosahedral asymmetric unit is marked with a black triangle in a and a single icosahedral protomer is drawn in b,
c. The maps of the procapsid and A-particle are essentially identical. c Atomic model of the A-particle capsid. The ribbon diagram demonstrates the pseudo
T= 3 arrangement of component proteins: VP1 (blue), VP2 (green) and VP3 (red). This color scheme is used throughout the manuscript unless noted
otherwise. d One segmented asymmetric unit of the A-particle density map (gray) fitted with its atomic model (Cα backbones) to highlight the densities
attributed to each individual protein. e The quality of the A-particle density map (gray) is illustrated by the fit of backbone and side chains for three
separate structural motifs: a β-strand (VP1), a loop (VP1) and an α-helix (VP2)
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capsid protein composition consistent with the presence of VP0,
VP1, and VP3 in sodium dodecyl supfate–polyacrylamide gel
electrophoresis (SDS–PAGE) gel electrophoresis (Supplementary
Fig. 1d, lane 2), and showed an absence of packaged genome as
verified by negative stain electron microscopy (Supplementary
Fig. 1e). These characteristics are all consistent with this band
being composed of purified procasids. The bottom band had a
λ260/λ280 absorbance ratio of 1.65 with particles sedimenting at
128S (Supplementary Fig. 1c) and composed of capsid proteins
VP1, VP2, and VP3 but no VP4 (Supplementary Fig. 1d, lane 3),
and contained packaged genome as verified by negative staining
(Supplementary Fig. 1f). It is well known that procapsids and
mature virions are typically the dominant types of picornavirus
particles harvested in vivo12. Mature virus (160S) contains one
copy of the genomic RNA and 60 copies each of capsid proteins
VP1, VP2, VP3, and VP4. Hence, the bottom band unexpectedly
contained particles more like uncoating intermediates (or A-
particles) as opposed to mature virions of other picornaviruses.
The thermal stability tests also confirmed this observation
(Fig. 1a). Of note, repeated rounds of isolation and purification
produced the same two bands of distinct but stable particles, and
as such we concluded that the CVA6 A-particles in the bottom
band represent a picornavirus anomaly.
The biological stability and infectivity of CVA6 procapsids and
A-particles were tested to determine if either or both of these
particles could serve as vaccine candidates. The protein melting
temperatures of both particles gradually rise as the pH is
progressively lowered from 8.5 to 5.5 (Fig. 1b, c). Procapsids and
A-particles remain stable throughout this pH range and are most
stable (melting point of ~65 °C) at pH 5.5 (Fig. 1b, c), which is
comparable to the acidic environment in the human gut during
infection. In addition, the high infectivity of the CVA6 A-particle
was measured to be 3.6 × 107 TCID50/mg, which demonstrates
that A-particles can infect cells efficiently (Fig. 1d). The above
results indicate that the isolated CVA6 A-particle is biochemically
similar to the uncoating intermediates of other picornaviruses,
but functions as a mature virus that has a stable structure and is
highly infectious.
Potent immunogenicity is an additional prerequisite for a good
vaccine candidate. To analyze the immunogenicity of CVA6
virus, mice were vaccinated with purified procapsids, A-particles
or heat-inactivated (HI) A-particles. Antisera elicited from all
three groups showed high and comparable neutralizing titers
against CVA6, indicating that all three of these particles exhibit
similar structures and antigenicity (Fig. 1e). In addition, the
therapeutic efficacy of antisera in vivo against CVA6 infection
was assessed using 1-day-old mice model. Three different antisera
all showed 100% treatment potential (P< 0.001) against a dose
(75 LD50) of CVA6 infection, whereas the control group started
to show signs of illness 5 d.p.i. and all died within 7 d.p.i. (Fig. 1f).
Hence, the similar antigenicity and potent therapeutic efficacy of
their antisera qualify both procapsid and A-particles as excellent
vaccine candidates against CVA6 infection.
Atomic models of CVA6 procapsid and A-particle. Purified
procapsid and A-particle samples were vitrified and imaged by
low-dose technique (Supplementary Fig. 2a, b). A total of 10,749
procapsid and 7152 A-particle images were extracted and sub-
jected to three-dimensional (3D) reconstruction, respectively,
yielding final density maps at estimated resolutions of 3.3 and 3.1
Å (Fig. 2a, b, Supplementary Figs 3a–f and 5, Table 1 and Sup-
plementary Movie 1). The density maps of the procapsid and A-
particle reveal essentially identical (0.96 correlation coefficient),
pseudo T= 3 icosahedral capsid structures, which explains why
the two particles share similar antigenicity. Their sizes are the
same too, with diameters being 290, 310, 330 Å, along their 2-, 3-,
and 5-fold axes, respectively (Supplementary Fig. 4). Densities
attributable to residue backbones and side chains, especially bulky
ones, were recognizable in both maps (Fig. 2e and Supplementary
Movie 1). The obvious difference between two density maps is the
density of genomic RNA, which is present in A-particles but
absent in procapsids (Supplementary Fig. 4). Atomic models of
their biological protomers (VP0 + VP1 + VP3 for the procapsid
and VP1 + VP2 + VP3 for the A-particle) were built manually and
subsequently refined by Phenix (Supplementary Fig. 5 and
Table 1). The structural similarity between the two atomic models
was deemed quite high as judged by their superposition (Sup-
plementary Fig. 6c) and confirmed by an r.m.s.d. value of 0.4 Å
between the two models. Though the procapsid was shown by
SDS–PAGE to contain VP0 (containing the sequences of VP2 and
VP4), only the VP0 sequence corresponding to VP2 is well
resolved in the density map and hence successfully modeled
(Fig. 2d and Supplementary Movie 1), indicating the one corre-
sponding to VP4 is flexible as that in previously reported EV71
procapsid12. Aside from this flexible region, both models contain
several additional coincidental flexible segments (Supplementary
Fig. 6 and Supplementary Table 1). Among these segments, seven
are identical and the others vary from 2 to 10 amino acid residues
(Supplementary Fig. 6a, b and Supplementary Table 1). The first
70 residues at the N-terminus of VP1 are missing in both models;
The AB loop of VP2 in the A-particle contains a flexible segment
of 10 a.a., but 20 a.a. in the procapsid; In VP3, one small segment
(a.a.74–77) is missing in the procapsid, whereas the
Table 1 CryoEM data collection and atomic models
refinement statistics
CVA6
procapsid
CVA6
A-particle
CVA6
A-particle-1D5
complex
Data collection
EM equipment Tecnai F30 Tecnai F30 Tecnai F30
Voltage (kV) 300 300 300
Detector Falcon II Falcon II Falcon II
Pixel size (Å) 1.128 1.128 1.128
Electron dose (e−/Å2) 25 25 25
Defocus range (μm) 1.3–4.0 1.0–4.3 0.7–4.1
Reconstructure
Software Relion 1.4 Relion 1.4 Relion 1.4
Number of used
particles
10,749 7,152 12,067
Final resolution (Å) 3.3 3.1 3.8
Model building
Software Coot Coot Coot
Refinement
Software Phenix Phenix Phenix
Model statistics
Correlation coefficient
(around atoms)
0.899 0.831 0.926
No. of atoms protein 4,799 4,909 6,733
Average B factor (Å2) −218.67 −163.92 −223.15
R.m.s.d.
Bond lengths (Å) 0.008 0.009 0.011
Bond angles (°) 1.19 1.27 1.21
Ramachandran plot
Favored (%) 97.13 96.06 94.07
Allowed (%) 2.87 3.94 5.57
Outliers (%) 0.00 0.00 0.36
Rotamer outliers (%) 0.00 0.00 0.00
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corresponding segment in the A-particle is intact (Supplementary
Fig. 6 and Supplementary Table 1). Atomic models of entire
capsids (Fig. 2c), except for the disordered regions identified
above, were generated using the program Chimera33.
The atomic model of the CVA6 A-particle reveals that it has a
similar capsid structure compared to other known picornavirus
A-particles (Fig. 3 and see also structure-based sequence
alignments in Supplementary Fig. 7). Indeed, the Cα positions
of 621 aligned residues of the CVA16 A-particle (PDB code
4JGY)14 and 618 aligned residues of the EV71 A-particle (PDB
code 4N43)25 when compared to the CVA6 A-particle gave
r.m.s.d. values of 0.8 and 0.9 Å, respectively (Supplementary
Table 2). The CVA6 A-particle contains characteristic structural
features that are typically attributed solely to picornavirus A-
particles. These include large, open channels at the icosahedral 2-
fold (2f-channel) and quasi 3-fold axes (q3f-channel) (Fig. 3a),
and a collapsed hydrophobic pocket beneath VP1 ‘canyon’.
However, close inspection of the CVA6 model also reveals several
significant structural differences from CVA16 and EV71 A-
particles as well as EV71 virions (PDB code 3VBS) (Fig. 3b, d).
CVA6 A-particle
a b
c d
e
CVA16 A-particle
EV71 A-particle EV71 mature virion
CVA6 A-particle CVA16 A-particle EV71 A-particle EV71 mature virion
BC loop HI loop
EF loop
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DE loop
HI loop
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BC loop
90°
Fig. 3 Structural comparisons of CVA6, CVA16, and EV71. a–d Close up views centered at a 2-fold axis (black ellipses) of atomic models of CVA6 A-particle
a, CVA16 A-particle b, EV71 A-particle c, and EV71 virion d. The 2f-channels (dashed squares) appear wide a, b, narrow c, and closed d. These comparisons
also demonstrate that the q3f-channels (dashed ellipses) are un-obstructed a, obstructed b, c, and closed d. e Superposition of VP1 surface loops of CVA6
A-particle, CVA16 A-particle, EV71 A-particle and EV71 mature virion. All four of these loops, especially the BC loop, exhibit prominent differences among
the different particles
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The 2f-channel in CVA6 has dimensions of 36 Å × 8 Å, which are
both similar to that in the CVA16 A-particle and the EV71 A-
particle (Fig. 3b, c), whereas the channel is closed in the EV71
virion (Fig. 3d). The q3f-channel in CVA6 is 23 Å × 13 Å in size,
but it is more obstructed in CVA16 and EV71 A-particles and in
EV71 virion. All three capsid proteins in the CVA6 A-particle
show regions of poor densities near the q3f-channel, such as the
GH loop (a.a. 205–217) in VP1, the AB (a.a. 43–52) and EF (a.a.
138–145) loops in VP2, and the GH loop (a.a. 173–188) in VP3
(Supplementary Fig. 6 and Supplementary Table 1).
The most significant differences among the three picorna-
viruses used for comparison occur at the four surface loops (BC,
DE, EF, and HI) of VP1 (Fig. 3e and Supplementary Movie 1). It
is well documented that five copies of VP1 associate together to
form a prominent protrusion on the capsid surface ‘cooling
tower’34 at each 5-fold vertex, and the four loops together form
the topmost portion of the 5-fold channel. The r.m.s.d. values in
the Cα positions for matched residues in these loops are 1.8, 1.9,
and 2.8 Å for comparison of the CVA16, EV71 A-particles and
EV71 mature virus, respectively, while the value is just 0.3 Å in
comparison to CVA6 procapsid (Supplementary Table 2); in
particular, the BC loop exhibits the largest differences among
these four particles, and the r.m.s.d. in the Cα positions for
matched residues in BC loop is 2.3, 2.0 and 3.2 Å, respectively
(Supplementary Table 2).
Capsid-RNA interactions involving the N-terminus of VP3. In
contrast to other known enteroviruses, CVA6 A-particles display
unique interactions between its capsid and the packaged gen-
ome14, 15, 26. The cryoEM density map and atomic model of the
A-particle together reveal that the N-termini of VP2 and VP3
interact with the genomic RNA near the icosahedral 2- and 5-fold
axes, respectively (Fig. 4a, b). Notably, the first 29 residues of the
VP2 N-terminus are not included in the atomic model since these
residues in each of the 60 copies of VP2 in the symmetrized
density map are not likely to interact equivalently with the single
copy of the genome. Two residues in VP2 lie closest to the
genome: E37 and W38 (Fig. 4c, d). The fact that VP2 W38
residues interact with the RNA near the 2-fold axes has also been
noted in other picornavirus A-particles26–28. In addition, strong
interactions between the N-termini of VP3 and the genomic RNA
were clearly apparent in the CVA6 A-particle density map. The
N-termini of five VP3 subunits extend beneath the VP1 ‘cooling
tower’ to form a well-defined annulus with the key residue P3
making close interactions with the genomic RNA (Fig. 4e).
Similar interactions between the VP3 N-termini and the genome
at the icosahedral 5-fold axes have been reported in picornavirus
Ljungan virus, HPeV1, HPeV335 and human rhinovirus28 but
have never been observed in any of the enterovirus species.
However, though VP1-mediated RNA contacts have been
reported in other picornaviruses14, 15, 25, none were detected in
the CVA6 A-particle in this study.
Atomic model of CVA6 A-particle-1D5 immune-complex. We
also used cryoEM and 3D image reconstruction methods to
investigate the structure of the CVA6 A-particle in complex with
the Fab portion of a previously identified neutralizing antibody
(nAb) 1D536. This antibody elicits a high neutralizing titer against
CVA6 (Supplementary Fig. 8a, b), and also exhibits a high
binding affinity for A-particles as revealed by an equilibrium
dissociation constant (KD) value of less than 10 nM (Supple-
mentary Fig. 8c). CryoEM images of CVA6 A-particles incubated
with excess Fab-1D5 clearly show particles with a halo of extra
density compared to purified A-particles (Supplementary Fig. 2c).
Two-dimensional (2D) classification of such images show well-
defined Fab density features that extend ~60 Å above the
CVA6 surface (Supplementary Fig. 2d). A total of 12,067 particle
images were extracted and subjected to 3D reconstruction
yielding a final density map at an estimated resolution of 3.8 Å
(FSC= 0.143)37 (Supplementary Fig. 3g–i and Supplementary
Movie 2). The density map shows that five Fab molecules encircle
the topmost edge of the ‘cooling tower’ at each 5-fold vertex, and
therefore a total of 60 Fab molecules can bind to each capsid
(Fig. 5a, b and Supplementary Movie 2). The variable domains
(directly contacting the capsid epitope) of the bound Fab mole-
cules exhibit density approximately as strong as that of the capsid
shell, which supports the notion that the Fab sites on the capsid
are nearly fully occupied. Also, as expected, owing to the flexible
connection between the constant and variable domain in the Fab,
the constant domains exhibit weaker density compared to the
capsid shell and the Fab variable domains (Fig. 5b and Supple-
mentary Fig. 9a).
The atomic model of the CVA6 A-particle-1D5 immune-
complex provides detailed views of several important features
including the Fab paratope, the virus epitope, the A-particle-Fab
interactions, and also Fab-Fab interactions (Fig. 5c–e, Supple-
mentary Fig. 9b, Supplementary Table 3, and Supplementary
Movie 3). Identification of a Fab interaction footprint site on the
virus surface was performed by the PISA program38, and the
interaction interface of each Fab covers an area of 675 Å2
(Supplementary Fig. 10). The interaction interface of Fab 1D5
involves five out of the six total complementary determining
regions (CDR) and one framework region (FR) in the light chain:
CDRL1, 2 and 3 and CDRH2, 3 and the FRL3 (between CDRL2
and CDRL3) (Fig. 5d, e). The A-particle-1D5 interaction interface
includes surface loops on two VP1 proteins from two adjacent
protomers. Each Fab interacts with the BC, EF and HI loops of
the nearest VP1 subunit and the DE loop of the counter-
clockwise-related (viewed from outside the complex) VP1. This
Fab-VP1 interaction includes an array of eight hydrogen bonds
and van der Waals interactions. The BC, EF, HI loops from one
VP1 and DE loop from an adjacent VP1 all hydrogen bond (H-
bond) to a single Fab (Fig. 5f–h and Supplementary Movie 3).
Aside from the above mentioned hydrogen bonds, residues on the
VP1 EF loop contribute the majority of van der Waals
interactions between CDRH and VP1.
The five Fab molecules aligned at each vertex H-bond to each
other via pairs of adjacent light chains (Fig. 5i). This H-bond
forms between the first residue of the light chain (ASP1) on one
Fab and TYR66, which lays 3 Å away on the light chain of an
adjacent Fab (anti-clockwise, viewed from outside the complex).
This network of five H-bonds acts to tether the otherwise flexible
N-termini of the light chains and forms a stable, wreath-like ring
of five Fabs. Notably, as we mentioned before, each Fab molecule
covers a footprint on epitope with a surface area smaller than an
average value of ~1000 Å2 39, which indicate an inferior binding
affinity between CVA6 A-particle and 1D5. However, such
wreath-like five-Fabs coalition covers a huge footprint (an area of
3375 Å) on the A-particle capsid surface, which is consistent with
the high binding affinity of 1D5. This might explain why the
CVA6 A-particle-1D5 is a rather stable immune-complex, which
enables its structure to be determined at high resolution.
1D5 prevents virus attachment to cell. To further explore the
mechanism by which 1D5 neutralizes CVA6, we examined
whether it could inhibit virus-cellular binding or interrupt the
post-attachment step of infection. A previously reported poly-
merase chain reaction with reverse transcription (RT-PCR) assay
was used to measure the number of virus particles bound to host
cells39. When pre-mixed with CVA6 virus particles, 1D5 reduced
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significantly the number of virus particles bound to the cell
surface with the inhibition level correlated directly with 1D5
concentration (Fig. 6a). Furthermore, similar inhibition by 1D5
was found when virus particles were allowed to bind to cells
before 1D5 was added, which indicates that 1D5 has much
stronger affinity to CVA6 particles than cell does (Fig. 6b).
1D5 seemed to be more efficient in blocking CVA6 from
attaching to cell surface than in competing against cell surface for
occupying the binding sites on virus particles.
At least up to the resolution (3.8 Å) of our cryoEM map, Fab-
1D5 binding induces no significant structural rearrangement of
the CVA6 capsid as revealed by their superposition of the
protomers in the CVA6 A-particle-1D5 complex and in A-
particle and also reflected by the r.m.s.d. value of 0.4 Å between
the Cα atoms of the two structures (Supplementary Fig. 9c and
Supplementary Table 2). Because the ring of five Fabs that
encircle the tip of each 5-fold vertex are connected by
intermolecular H-bonds, this may act to stabilize the capsid and
prevent conformation changes required for genome release. The
fluorescence-based thermal stability assays appear consistent with
this hypothesis given that CVA6 immune-complexes melt at a
1 °C higher temperature than virus particles in the absence of Fab
or Ab binding (Fig. 6c).
The epitope recognized by the 1D5 was also shown to be an
immune-dominant antigenic site. Antisera against CVA6 pro-
capsid, untreated A-particle or heat inactivated A-particles were
prepared and used to probe competitive binding of 1D5. All three
antisera could similarly and efficiently inhibit binding of 1D5 to
CVA6 procapsid (58.7%, 50.2% and 57.9%) or A-particle (62.9,
41.6 and 58.0%) (Fig. 6d). The above results indicate that 1D5
binds to an immune-dominant site on CVA6.
Discussion
Picornaviruses primarily exist non-infectious, empty procapsids
and infectious, mature virions in infected host cells. Upon
attachment to specific receptors on the host cell surface during
the initial stage of the infection in vivo, virions expand and
transform into A-particles14, 26. Such a transformation can also
be induced in vitro when virions are treated with heat, low pH
or allowed to interact with receptor15, 24, 26, 40, 41. To date, A-
particles have been characterized as necessary entry inter-
mediates during infection. The atomic structure of A-particle for
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CVA16 has been reported previously, but the conversion
occurred without any treatment in only one batch of multiple
isolations and not yet be duplicated14. In this study, however,
CVA6 procapsids and A-particles can be obtained by routine
methods of continuous, sucrose density gradient ultra-
centrifugation. CVA6 A-particles isolated and purified in this
manner exhibit the biochemical composition and structural
features similar to the A-particles of other picornaviruses.
Indeed, these CVA6 A-particles have a sedimentation coefficient
of 128S, which is similar to 135S of A-particles for most
picornavirions. Also, like A-particles, the VP4 capsid protein is
absent in these CVA6 A-particles and they have an elongated 2f-
channel and collapsed pocket factor binding site. However,
unlike the elusive A-particles, CVA6 A-particles are
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biochemically and structurally stable both in vivo and in vitro
while remaining infectious and immunologically active.
Specific receptors have been identified for many picorna-
viruses31, 32, but the receptor for CVA6 has not yet to be iden-
tified. Picornavirus receptors typically bind to the highly exposed
surface loops of the capsid proteins, which also often serve as the
viral neutralizing epitopes. The binding sites of the poliovirus or
rhinovirus receptors have been identified on the BC or HI loops
of VP142–44. EV71 and CVA16 both employ SCARB2 and PSGL-
1 as their cellular receptors31, 32. For EV71, SCARB2 has been
shown to bind in the canyon or ‘pocket’ region on the EF loop of
VP145. Hence, VP1 surface loops appear to be a preferred
receptor-binding site in many picornaviruses. Obviously, com-
parisons of the CVA6, EV71 and CVA16 capsid structures show
that the prominent differences among these structures map to the
BC, DE, EF and HI loops of VP1. Therefore, distinct arrange-
ments of these four loops among different picornavirus species
creates numerous unique capsid surfaces and likely explains why
CVA6 does not share the same receptors with EV71 or CVA16.
The atomic model of the CVA6 A-particle-1D5 complex clearly
demonstrates that these loops also serve as the viral neutralizing
epitope, and 1D5 has the ability to disrupt binding or attachment
of CVA6 to host cells. This suggests that the CVA6 receptor-
binding site may be at or close to the VP1 surface loops.
Furthermore, the VP1 loops would appear to be excellent targets
for designing specific antivirals against CVA6.
It is well established that mature picornavirus particles undergo
significant structural expansion during the uncoating process as
they transform into A-particles that release the genomic RNA
into host cells12, 14, 15. Here, the CVA6 A-particle examined in
this study, unlike the classical, mature picornavirion and instead
more like a stable uncoating intermediate, may require only
minimal conformational change in its capsid to enable release of
the genomic RNA. Hence, the RNA in CVA6 A-particles may be
more primed for release compared to the packaged RNA in
mature virions of other known picornaviruses. In fact, the capsid-
RNA interactions revealed in our CVA6 cryoEM density maps
might provide some clues as to where the genome exits the capsid
as it is released into host cells. As our results show, the N-
terminus of VP3 in the CVA6 A-particle forms strong interac-
tions with the genome at the icosahedral 5-fold vertices, which is
unique among all the known enteroviruses14, 15, 26. In turn, the
binding of five Fab-1D5 molecules at each CVA6 vertex can not
only neutralize the CVA6 A-particle but it might also stabilize the
capsid and thereby restrict conformational changes necessary to
allow RNA release. We also noted that such VP3-RNA interac-
tion was observed in A-particles of rhinovirus captured at its
near-physiological conditions by acidification of mature
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rhinoviruses (as occurs in the endosome) as well28. However,
unlike these unstable rhinovirus A-particles, CVA6 A-particles
are readily harvested in vivo and remain stable in buffer (pH 5.5)
that mimics the optimal physiological environment of the human
gut. This might be one of the reasons that CVA6 adopts A-
particle, rather than mature virus, as its stable being in its life
cycle. In this study we have shown that CVA6 exhibits several
unique properties that identify it as an anomalous member of the
family Picornaviridae.
The cryoEM structures of the CVA6 procapsid, A-particle, and
A-particle-1D5 immune-complex we report here reveal atomic
resolution details about molecular determinants in CVA6 related
to virus neutralization, cell binding, and RNA release. These
details also suggest that procapsids and A-particles (heat-treated)
might serve as excellent vaccine candidates against HFMD.
Finally, studies like this one, in which the detailed interaction
interface between a virus and antibody is directly visualized,
highlight the prediction by Earl and Subramaniam46: “cryoEM is
likely to increasingly become a routine tool to aid rapid vaccine
design, especially icosahedrally symmetric viruses”.
Methods
Virus production and purification. CVA6 strain TW-2007-00141 (GenBank
accession no. KR706309 that was first isolated in 2007) in Taiwan was grown in RD
cells at a multiplicity of infection (MOI) of 0.1. Virus was harvested 3 days post
infection, centrifuged to remove cell debris, ultrafiltered. The virus supernatant was
mixed with 50% polyethylene glycol 8000 (PEG 8000) and 2M NaCl-phosphate-
buffered saline (PBS) (pH 7.4) to final concentrations of 8% and 300mM,
respectively, and stirred overnight at 4 °C. After centrifugation and removing the
pellet, the CVA6 virus particles were loaded onto a 15–45% (w/v) sucrose density
gradient and centrifuged at 153,900 g for 4.5 h in a Beckman SW41 rotor at 4 °C.
Two sets of fractions were independently dialyzed against PBS buffer and further
concentrated. The quantity of virus particles were then estimated by its UV
absorption level at a wavelength of 260 nm using UV spectroscopy. The protein
composition was analyzed with SDS–PAGE. The concentration and homogeneity
of the particles were also examined by negative-stain electron microscopy.
PaSTRy assay. Thermofluor experiments47 were performed with a MX3005p RT-
PCR instrument (Agilent/Stratagene). Fluorescent probe SYTO9 and SYPROred
(both from Invitrogen) were used to detect the presence of single-stranded RNA
and exposed hydrophobic regions of capsid proteins respectively. Multiple reaction
mixtures, each with a total volume of 50 μl, containing 1.0 μg of virus particles, 5
μM SYTO9 and 3 × SYPROred, but with different a pH scale (ranging 5.5 to 8.5, 0.5
interval), were set up in thin-walled PCR plates (from Agilent). The fluorescence
level was recorded in triplicate at 0.5 °C intervals from 25 to 99 °C. In addition, a
similar thermal stability assay was also performed on virus-Fab or virus-Ab
immune complexes with 1.0 μg of CVA6 particles pre-incubated with either anti-
body or Fab (with a final antibody/fab concentration of 50 μg ml−1) at 37 °C for 1 h.
The temperatures at which RNA was released (Tr) and at which particles melted
temperature (Tm) were recorded as the minimums of the negative first derivative
of the RNA exposure and protein denaturation curves, respectively.
Vaccine preparation and immunization of mice. The purified CVA6 A-particles
were inactivated by heating at 56 °C for 30 min (heating causes RNA release,
producing non-infectious particles48 and their immunogenicity was evaluated in
mice. Four groups of mice (n= 6 per group) were respectively immunized (two
doses, 3 weeks apart) with aluminum adjuvant (control), CVA6 procapsids, CVA6
A-particles, or pre-heated CVA6 A-particles. Sera were inactivated by incubation at
56 °C for 30 min, and stored at −20 °C for ELISA and neutralization assays.
In vitro neutralization assay. RD cell monolayers were diluted in MEM supple-
mented with 2% FBS and then seeded into 96-well plates (NUNC) (~10,000 cells
per well). Different concentrations of mAbs, Fab fragments, or HI mouse sera were
diluted in MEM by 2-fold serial dilutions ranging from 1:8 to 1:4,096, and each well
was incubated in 1:1 volume ratio with infectious CVA6 strains (100 TCID50) for 1
h at 37 °C. Each sample was then incubated with the prepared RD cells in 96 well
plates at 37 °C and was inspected for the CPE phenomenon in infected cells for
3 days. The neutralization titers were the averages of the triplicates calculated based
on the highest dilution in over 50% CPE.
Pre- and post-attachment inhibition assays. For pre-attachment inhibition
assays, serially diluted 1D5 was incubated together with CVA6-141 (5 × 104
TCID50) for 1 h at 4 °C. The mixture was then added to 105 RD cells which had
been pre-seeded one day ahead in a 96-well plate and incubated for 1 h at 4 °C. The
infected cells were washed three times with cold PBS buffer to remove unbound
virus. For the post-attachment inhibition assay, CVA6-141 virus was added to RD
cells and incubated for 1 h at 4 °C. The virus-bound cells were washed twice with
cold PBS buffer, mixed with serially diluted 1D5, incubated for 1 h at 4 °C and
washed three times again. The amount of CVA6 was estimated by a one-step,
quantitative RT-PCR as previously described49. In brief, RNA was extracted using
the QIAamp Mini viral RNA Extraction Kit (Qiagen, Inc. Hilden, Germany) fol-
lowing the manufacturer’s instructions. RT-PCR reaction was performed using the
CFX96 Real-Time PCR Detection System (Bio-Rad). The total 50 μl reaction
volume contained 0.5 μl each of 10 mM forward (5′-TACTTTGGGTGTCCGT
GTTT-3′) and reverse primers (5′-TGGCCAATCCAATAGCTATATG-3′), 0.2 µM
of the probe (5′-FAM- AYTGGCTGCTTATGGTGACRAT-BHQ1-3′), 3.2 mM of
dNTP, 4 µl of 10 × buffer (Mg2+ plus), 1 U of Taq HS DNA polymerase, 0.4 U of
AMV reverse transcriptase and 5 µl of extracted RNA template. The thermal profile
for RT-PCR was 15 min of reverse transcription at 50 °C; 10 min of denaturation at
95 °C; 40 cycles of 95 °C for 15 s, and 55 °C for 45 s. The analysis of relative levels of
CVA6 RNA in different samples was performed by the comparative 2-ΔΔCT
method50.
Competitive ELISA. The sera from mice immunized with CVA6 particles were
used for the competitive ELISA assay. The sera from mice (at 1:100 dilution) were
added to the wells coated with purified CVA6 particles in blocking solution (final
volume: 50 μl per well), and the plates were incubated for 30 min at 37 °C. HRP-
conjugated 1D5 (1:5000 dilution) was then added and incubated at 37 °C for 30
min. The OD value was converted to percentage inhibition (PI) using the following
formula: PI (%)= 100−[(ODsample/ODcontrol) × 100], where the OD of the control
well represents the well containing only HRP-conjugated 1D5.
CryoEM image acquisition. Immune complex were prepared by mixing CVA6 A-
particle (1.4 mgml−1) with 1.2-fold excess of Fab-1D5 (MW= ~50 kDa, 108 a.a.
and 119 a.a. corresponding to light and heavy chains of the variable domain)
fragment (equivalent to a molar ratio of 1:72), then incubated at 37 °C for 2 h.
Aliquots (3 μl) of purified samples of procapsid, A-particle or immune complex
were deposited onto glow discharged holey carbon Quantifoil Cu grid (R2/2, 200
mesh, Quantifoil Micro Tools) inside an FEI Mark IV Vitrobot at a humidity level
of 100%. After 6s blotting, the grid was plunge-frozen into liquid ethane cooled by
liquid nitrogen, and then examined under low-dose conditions at 300 kV with an
FEI Tecnai F30 transmission electron microscope. All images were recorded on a
Falcon II direct electron detector (seven-frame movie mode) with the defocus
settings ranging between 1.5 and 3.0 μm underfocus and at a nominal magnifica-
tion of 93,000 (corresponding to a pixel size of 1.128 Å). The total electron dose
was set to 25 e− Å−2 with an exposure time of 1 s. The FEI EPU automated data
collection software was used for all data acquisition, and micrographs with
excessive drift or astigmatism were discarded. A total of 312 micrographs for CVA6
procapsid, 203 micrographs for the A-particle and 1085 micrographs for the
immune complex were selected for further image processing.
CryoEM single particle 3D reconstruction. Movie frames alignment and CTF
estimation of each aligned micrograph were carried out with the program
Motioncorr51. and Ctffind352. A total of 23,172 CVA6 procapsid, 9993 CVA6 A-
particles and 13,765 immune complex particles were manually boxed using the
e2boxer.py routine in the EMAN2.1 package53. Initial 3D models of each of the
three kinds of particle were generated with random model method using
AUTO3DEM54. Two rounds of reference-free 2D classification, several rounds of
unsupervised 3D classification and final 3D density map reconstruction were all
performed with RELION 1.455. A total of 10,749 selected procapsid images,
7152 selected A-particle images and 12,067 CVA6 immune complex particle
images were included in final 3D reconstructions respectively. The resolutions of
the final maps were estimated based on the gold-standard FSC curve with a cut-off
at 0.14337. Local resolution variations were estimated using ResMap56.
Model building and refinement. The atomic models of all three particles were
manually built in Coot and then refined with Phenix57, 58. The crystal structure of
the CVA16 virus protomer (PDB code 4JGY)14 was used as a homology model and
manually fitted into the segmented volume (including an asymmetric unit) of the
final cryoEM map using Chimera33, whereas a de novo modeling procedure was
performed on the final cryoEM map of the CVA6 A-particles-1D5 complex.
Atomic positions of residues were built and modified using the Coot software
package and further refined using Phenix in real space to maximize the correlation
coefficient between the EM density map and a calculated map based on the
coordinates of all atoms. The above procedure was iteratively repeated five times to
achieve the optimized atomic model of one asymmetric unit. Model statistics,
including bond lengths, bond angles, all atom clashes, rotamer statistics, Rama-
chandran plot statistics, etc, were closely inspected with Coot during the whole
process. Visualization, segmentation of density maps, and generation of animation
movies were performed with Chimera33. Fab density in the difference maps were
projected on a stereographic sphere using RIVEM59. The Fab 1D5-CVA6 inter-
actions were analyzed using Chimera and the PISA38 server (www.ebi.ac.uk/pdbe/
pisa) with the donor to acceptor distances <4 Å for hydrogen bonding interactions.
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Cell lines and media and viruses. Human embryonal RD cells (from American
Type Culture Collection) were cultured in Minimal Essential Medium (GIBCO)
supplemented with 10% FBS (GIBCO). The CVA6 strain was isolated from throat
and anal swabs of HFMD patients in Taiwan. CVA6 stock was propagated in RD
cells and the supernatant was harvested and stored at −80 °C. Virus was titrated by
a plaque assay using RD cells. Virus samples were added to RD cells in 96-well
plates and incubated at 37 °C for 7 days. Then the 50% tissue culture infectious
doses (TCID50) values were measured by determining CPE and calculated
according to the Behrens-Kärber method.
SDS–PAGE. The purified CVA6 particles were analyzed by SDS–PAGE. Virus
particles were mixed with the 4 × NuPAGE LDS sample buffer and 10 × reducing
agent (Invitrogen). Sample mixtures were heated at 70 °C for 10 min before loaded
onto a NuPAGE 4-12% Bis-Tris Gel (Invitrogen).
Negative staining electron microscopy. The purified CVA6 particles solution at a
concentration of 0.1 mgml−1 were deposited onto a carbon-coated grid for 1 min
and the excessive solution was removed with filter paper. The grid was washed
twice with double distilled water and then immediately negatively stained for 30 s
with freshly filtered 2% phosphotungstic acid (pH 6.4). Grids were examined with
the FEI Tecnai T12 TEM at an accelerating voltage of 120 kV and photographed at
a magnification of 25,000.
Analytical ultra-centrifugation. The homogeneity and molecular mass of the
CVA6 viral particles were estimated by the value of sedimentation velocity (SV)
achieved with AUC. CVA6 viral particles were first diluted to 0.2 mg ml−1 in PBS
buffer, AUC analysis was performed at 4 °C with Beckman XL-A analytical
ultracentrifuge, equipped with absorbance optics and an An60-Ti rotor (22,700 g).
A total of 150 scans for each sample were recorded and the sedimentation coef-
ficient and f/f0 were obtained with the c(s) method60 using the Sedfit software
(kindly provided by Dr P. Schuck, National Institutes of Health, http://www.
analyticalultracentrifugation.com).
SPR. The binding of 1D5 to CVA6 A-particles was analyzed by SPR using a
BIAcore 3000 biosensor (GE Healthcare Life Sciences). The affinity measurements
of 1D5 binding with CVA6 A-particles were initiated by passing HBS (10 mM
HEPES, pH 7.4 and 150 mM NaCl) over the sensor surface for 100 s at 5 μl min−1,
followed by injection of 5 μg ml−1 of 1D5 at 30 μl min−1 for 2 min. Serially diluted
A-particles were then injected at concentrations of 0, 0.172, 0.345, 0.69, 1.38 and
2.76 nM, at a flow rate of 30 µl min−1 for 3 min, and then allowed to dissociate over
2 min. Binding curve at the zero concentration of particle was subtracted as a blank
from each experimental curve. Data were analyzed using BIA evaluation 4.1 soft-
ware. Kinetic constants, ka and kd, were estimated by global fitting analysis of the
association/dissociation curves to the 1:1 Langmuir interaction model.
Preparation of Ab-1D5 and Fab-1D5. To obtain the anti-CVA6 monoclonal
antibody (1D5), mice were immunized with CVA6-00141 emulsified in Freund’s
adjuvant. Two booster immunizations were performed on days 14 and 28. After
final boost, fusion of splenocytes with Sp2/0Ag-14 myeloma cells were performed.
Then the hybridoma supernatants were screened by indirect ELISA and neu-
tralizing test against CVA6. Purified 1D5 was got from mouse ascitic fluid by
purifying with protein A column. The 1D5 was conjugated to horseradish perox-
idase (HRP) by the NaIO4 oxidation method and stored at −20 °C.
The RNA was isolated from 1D5 hybridoma cells and converted to cDNA by
reverse transcription. Then, the variable regions of the heavy chain and light chain
of 1D5 were amplified by PCR for sequence determination. The Fab-1D5 fragment
was digested with papain at a weight ratio 800:1 in 20 mM phosphate buffer (pH
7.0) containing 30 mM L-Cys and 50 mM EDTA for 10 h at 37 °C before adding 30
mM iodoacetamide to stop the reaction. The resulting Fab fragment was then
purified using DEAE-5PW (TOSOH).
Binding ELISA. The 96-well plates were coated with 50 ng/well of purified CVA6
procapsids and A-particles (0.5 μg ml−1 in PBS buffer) or CVA6-infected RD cell
lysates and incubated at 4 °C for 12 h. The plate was then washed with PBS con-
taining 0.05% Tween 20 and 1% bovine serum albumin in PBS for 2 h at 37 °C to
minimize the nonspecific binding. The antibodies were then added at various
concentrations. The serum with 10-fold dilution series (the first dilution was 100-
fold), were added to the wells and incubated for 30 min at 37 °C. The horseradish
peroxidase-conjugated goat anti-mouse (GAM-HRP) IgG antibody/well in a
1:5,000 dilution was then added and incubated for 30 min at 37 °C as well. After
color development, absorption was measured at A450/620.
Data availability. Atomic coordinates of CVA6 procapsid, A-particle and A-
particle-1D5 complex have been submitted to the Protein Data Bank with accession
numbers 5XS5, 5XS4 and 5XS7, respectively. The cryo-EM density map has been
deposited with the Electron Microscopy Data Bank 6752, 6751 and 6757, respec-
tively. Additional data that support the findings of this study are available from the
corresponding authors upon reasonable request.
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